Lymphir — denileukin diftitox-cxdl
Named-patient access overview. Lymphir is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Lymphir
Lymphir (denileukin diftitox-cxdl) is manufactured by Citius and indicated for R/R CTCL. It is a IL-2 fusion toxin approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Lymphir
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Lymphir for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Lymphir is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Lymphir in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Lymphir in BangladeshNamed-patient access, timeline, and regulatory notes
Lymphir in IndiaNamed-patient access, timeline, and regulatory notes
Lymphir in KuwaitNamed-patient access, timeline, and regulatory notes
Lymphir in United Arab EmiratesNamed-patient access, timeline, and regulatory notes
Start a request for Lymphir
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.